The world of anesthesia is evolving, and pain management is at the forefront of this transformation. In this episode, we dive into the revolutionary non-opioid analgesic, Suzetrigine, a selective NaV1.8 inhibitor making waves in perioperative and acute pain management. With increasing pressure to reduce opioid dependence while maintaining effective pain control, anesthesia providers must stay ahead of cutting-edge developments. Join us as we break down the pharmacology, safety profile, clinical trial data, and real-world implications of this game-changing drug. Here’s some of what we discuss in this episode: We’ll talk about dosing in extreme detail because, as anesthesia providers, we know that precision matters. The drug interactions is a critical consideration and we’ll run through adjustments that need to be made. We get to the into the physiology and pharmacology implications of Suzetrigine, focusing on what this means for nurse anesthetists. The pharmacological properties of Suzetrigine and how it functions at a molecular level to modulate pain perception. The side effects and contraindications. Scientific trials and comparisons to other analgesics for nurse anesthetists. Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here: https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246 Donate to Our Heart Your Hands here: https://www.ourheartsyourhands.org/donate Support Team Emma Kate: https://grouprev.com/haloswalk2024-shannon-shannon-brekken

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related